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Abstract: Constantly increasing prevalence of allergic diseases determines the attempts to elaborate the 
therapeutic strategies activating immune tolerance to particular allergen. Our current research focuses 
on the antigen-specifi c action of CD8+ suppressor T (Ts) lymphocytes induced in mice by intravenous 
administration of a high dose of haptenated syngeneic erythrocytes. While the regulatory activity of Ts cells 
mediated by exosome-delivered miRNA-150 is well defi ned, the mechanism of their induction remained 
unclear. Th erefore, the current studies investigated the immune eff ects induced in mice by intravenous 
administration of contact allergens coupled to syngeneic erythrocytes. In mouse models of hapten-induced 
contact hypersensitivity (CHS) and delayed-type hypersensitivity to ovalbumin, we have shown that 
intravenous administration of hapten-coupled erythrocytes failed to induce CHS eff ector cells. Moreover, 
hapten-induced CHS reaction occurred to be suppressed in mice intravenously administered with syngeneic 
erythrocytes coupled with protein allergen. Finally, we have demonstrated that intravenously administered 
allergen induces immune tolerance only when bound to syngeneic erythrocytes, proving that intravenously 
delivered allergens are deprived of their immunizing properties when coupled with membrane of self cells. 
Altogether, our current studies suggest that alteration of self cell membrane by allergen binding is enough 
to induce Ts cell-mediated immune tolerance to nonpathogenic agents, which express a great translational 
potential in such conditions as allergies and hypersensitivity-related autoimmune disorders.
Key words: allergen, allergy, contact hypersensitivity, delayed-type hypersensitivity, immune suppression, 
immune tolerance, sensitization, suppressor T cells, tolerogen.
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Introduction
Th e increasing prevalence of allergies and hypersensitivities, including contact 
allergy, became at present one of the most recognizable adverse eff ects of economic 
development of societies and environmental pollution to human health. As estimated, 
more than 20% of people of the general population suff er from contact allergy [1], 
which is associated with an increased frequency of exposure to common allergens 
present in house and workplace environment, in food, drugs and other consumer 
goods. While generally available and most commonly used means of treatment of 
allergic patients usually induce the state of antigen-non-specifi c immune suppression, 
current studies attempt to elaborate the therapeutic strategies activating immune 
tolerance to particular allergen, and remaining the responsiveness of immune cells to 
other antigens unaff ected.
While haptenated proteins possess immunostimulatory and allergy-inducing 
properties [2], haptens bound to membrane structures of self cells were suggested 
to act as tolerogen [3]. Along these lines, our current research focuses on the 
action of CD8+ suppressor T (Ts) lymphocytes induced in mouse model of contact 
hypersensitivity (CHS), a cutaneous manifestation of delayed-type hypersensitivity 
(DTH) that refl ects human contact dermatitis [4], by intravenous administration of 
a high dose of haptenated syngeneic erythrocytes [5–8]. Ts cells have been already 
proved to suppress hapten-induced CHS reaction in a hapten-specifi c manner by the 
release of miRNA-150 contained in exosomes coated with hapten-specifi c antibody 
free light chains (LCs) [5], ensuring the specifi city of induced suppressive eff ect [7]. 
Similarly, our recent research fi ndings showed that exosome-carried miRNA-150 also 
antigen-specifi cally down-regulates mouse DTH response to food allergens, such as 
ovalbumin (OVA) and casein [9, 10]. Exosome-carried miRNA-150 target antigen 
presenting cells, likely by binding antigenic determinants complexed with surface 
MHC molecules via LCs of corresponding specifi city [11], which in turn inhibit 
eff ector T cells of immune response [8, 12]. Th us, due to the generation of suppressive 
exosomes, Ts cells are able to activate long-lasting immune tolerance to particular 
antigen determined by the specifi city of LCs coating exosomes and produced by B1 
cells at the time of sensitization with antigen [6, 7, 13]. Th is mechanism seems to have 
a great translational potential in allergen-specifi c therapy of contact allergy. However, 
while the regulatory activity of Ts cell-derived exosomes delivering miRNA-150 is well 
defi ned [5–12], the mechanism of induction of Ts cells by intravenously administered, 
hapten-coupled syngeneic erythrocytes remains still weakly understood. Th erefore, 
the current studies have been undertaken to investigate the immune eff ects induced in 
mice by intravenous administration of DTH-eliciting allergens coupled to syngeneic 
erythrocytes.
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Materials and Methods
Nine to twelve week-old CBA mice either from the Breeding Unit of Faculty of 
Medicine of the Jagiellonian University Medical College (Krakow, Poland) or from 
Jackson Laboratories (Bar Harbor, ME) were subjected to experiments according to 
the guidelines of the 1st Local Ethics Committee (approval number 39/2011, 40/2011 
and 106/2012) and the Institutional Animal Care and Use Committee of the Yale 
University, New Haven, CT (Permit Number 07381). Each experiment was repeated 
at least twice and representative results were interpreted and depicted in the fi gures.
Freshly collected mouse syngeneic erythrocytes were conjugated with trinitroph-
enyl (TNP) hapten by resuspending of 1 ml of erythrocyte pellet in 7 ml of trini-
trobenzene sulphonic acid (Eastman Chemicals, Rochester, NY) solution in cacodylic 
buff er (5.7 mg/ml), and incubating 20 minutes at room temperature on hematological 
roller and in darkness. Similarly, erythrocytes in 10 ml of 10% DPBS suspension were 
coupled with oxazolone (OX) hapten (Sigma, St Louis, MO) by mixing with 20 ml 
of OX solution, prepared earlier by dissolving 10 mg of OX sample in 1 ml of 96% 
ethanol and then in 20 ml of boiling DPBS, and incubating for 10 minutes in analo-
gous conditions. Finally, erythrocytes were labelled with protein antigens, i.e. OVA or 
bovine serum albumin (BSA), both from (Sigma, St Louis, MO), by modifi ed method 
of Jandl and Simmons [14]. Briefl y, 1 ml of 50% DPBS suspension of mouse eryth-
rocytes was mixed with 5 ml of 1% OVA or BSA solution in DPBS containing Cr3+ 
ions from 2.5 micromolar solution of CrCl3, and incubated for 1 hour in the same 
conditions. Where indicated, erythrocytes were incubated only in the presence of Cr3+ 
ions, in the corresponding volume of DPBS. Aft er washing, resuspending in DPBS 
and fi ltration through nylon mesh, erythrocytes were used for intravenous adminis-
tration as allergen-coupled mouse syngeneic erythrocytes (MRBC), i.e. TNP-MRBC, 
OX-MRBC, OVA-MRBC or BSA-MRBC, respectively, or as chromium-treated eryth-
rocytes (Cr3+/MRBC).
Mice were injected intravenously on day 0 and 4 with 0.2 ml of 10% DPBS 
suspension of allergen-coupled MRBC or chromium-treated MRBC, or, where 
indicated, with 1 mg of OVA in 0.2 ml of DPBS. Th ree days later mice were either 
contact sensitized by topical application of 0.15 ml of 5% trinitrophenyl chloride 
(picryl chloride, PCL, Chemtronix, Swannanoa, NC) or 3% OX solution in a mixture 
of ethanol and acetone (3:1 v/v) on shaved abdominal skin [5–8], or immunized by 
4 intradermal injections of 0.05 ml of 0.5 mg/ml OVA solution in physiological saline 
on 2 consecutive days [15]. In some instances, recipients of TNP-MRBC remained 
not sensitized prior to ear challenge. Aft er 5 days mice were ear challenged to elicit 
CHS or DTH responses, respectively, by topical application on each side of both ears 
of 10 μl of 0.4% PCL or OX in a mixture of acetone and olive oil (1:1 v/v), or by 
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intradermal injections into both ears of 10 μl of a 0.5 mg/ml OVA solution in saline. 
Twenty four hours later ear swelling was measured with an engineer’s micrometer 
(Mitutoyo, Japan) by an observer unaware of experimental protocol [16]. Background 
ear thickness was then subtracted to calculate ear thickness increase for each mouse. 
Aft erwards, nonspecifi c increase in thickness of ears of non-sensitized but challenged 
littermates, caused by chemical irritation of skin by antigen and its vehicle, in most 
cases was subtracted from experimental groups to calculate a net value of ear swelling 
expressed as delta ± standard error (SE) [U × 10–2 mm]. Statistical signifi cance of 
the diff erences observed between groups was estimated, when test assumptions were 
accomplished, in Analysis of Variance (ANOVA) with post hoc RIR Tukey test and 
p <0.05 was considered statistically signifi cant.
Results
Intravenous administration of hapten-coupled erythrocytes failed
to induce CHS eff ector cells
Previous research fi ndings unequivocally proved that intravenous administration 
of hapten-coupled syngeneic erythrocytes prior to contact sensitization with the 
same hapten leads to the suppression of subsequently elicited CHS reaction [3] by 
activation of Ts cells releasing regulatory miRNA-150 in exosomes [5–12]. However, it 
was undefi ned whether intravenously delivered hapten-coupled erythrocytes may also 
induce CHS eff ector cells, similarly to haptenated proteins [2]. To test this assumption, 
recipients of TNP-MRBC were remained not sensitized prior to ear challenge with 
TNP hapten that presumably should elicit CHS ear swelling. Notably, the resulting 
increase in ear thickness of TNP-MRBC-administered mice was comparable to this 
measured in similarly challenged, non-sensitized littermate animals, which results only 
from chemical irritation of skin by hapten solution, while the ear thickness increase 
caused by infl ammatory reaction of CHS eff ector cells in hapten-sensitized mice was 
signifi cantly higher (Fig. 1, Groups C and A vs B). Th is observation undoubtedly 
proves that intravenous administration of erythrocytes coupled with hapten does 
not induce CHS eff ector cells. Instead, this mean of treatment leads to induction of 
immune tolerance mediated by Ts cells.
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Fig. 1. Hapten-coupled syngeneic mouse red blood cells (MRBC) failed to induce contact hypersensitivity 
(CHS) eff ector cells aft er intravenous (iv) administration. Mice were injected intravenously on day 0 
and 4 with 0.2 ml of 10% DPBS suspension of trinitrophenol (TNP)-coupled MRBC. On day 7 mice 
of positive control group were epicutaneously (ec) sensitized with 0.15 ml of 5% trinitrophenyl chloride 
(picryl chloride, PCL) solution. Th en, on day 12 mice of all groups were ear challenged with 0.01 ml of 
0.4% PCL solution to elicit CHS ear swelling, measured 24 hours later with an engineer’s micrometer. 
Results are shown as mean increase of ear thickness [U × 10–2 mm] ± standard deviation (SD). One-way 
ANOVA with post hoc RIR Tukey’s test; *** p <0.005.
Hapten-induced CHS reaction is suppressed in mice intravenously 
administered with syngeneic erythrocytes coupled with protein allergen
Allergy to red meat with immediate and delayed onsets is observed in humans [17], 
and BSA is considered as one of potential allergens. Furthermore, methylated BSA 
was recently shown to induce DTH response in mice [18]. Conversely, we have 
recently found that suppression of TNP-induced CHS reaction could be achieved by 
intravenous administration of syngeneic erythrocytes coupled with protein antigen, 
namely BSA. It was assumed that the specifi city of induced suppression depends 
on the hapten used for further epicutaneous sensitization, since it activates B1 cell 
secretion of specifi c LCs coating the regulatory exosomes, and that coupling with 
protein antigen is enough to alter self antigens of syngeneic erythrocytes to make 
them tolerogenic [7]. However, it was unclear whether this phenomenon generally 
applies to hapten-induced CHS response or depends on hapten used for subsequent 
sensitization. To verify these doubts, we have intravenously administered mice with 
BSA-MRBC prior to contact sensitization with OX hapten, that is non-cross reactive 
with TNP [3, 5, 6]. Accordingly, CHS ear swelling reaction elicited by challenge with 
OX was similarly suppressed in both, mice tolerized with OX-MRBC and BSA-MRBC 
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(Fig. 2, Groups B and C vs A). Th is strongly suggested that alteration of syngeneic 
erythrocytes by binding of protein allergens is also effi  cient to induce Ts cells 
suppressing CHS response to various haptens, when such tolerogen is delivered via 
intravenous route.
Fig. 2. Syngeneic mouse red blood cells (MRBC) coupled with bovine serum albumin (BSA) suppress 
oxazolone (OX)-induced contact hypersensitivity (CHS) response aft er intravenous (iv) administration. 
Mice were injected intravenously on day 0 and 4 with 0.2 ml of 10% DPBS suspension of either 
BSA-MRBC or OX-MRBC. Th ree days later mice were epicutaneously (ec) sensitized with 0.15 ml of 
3% OX solution, and on day 12 mice were ear challenged with 0.01 ml of 0.4% OX solution to elicit 
CHS ear swelling, measured 24 hours later with an engineer’s micrometer. Results, aft er subtracting of 
background increase of ear thickness in non-sensitized but challenged mice, are shown as delta; i.e. net 
value of ear swelling [U × 10–2 mm] ± standard error (SE). One-way ANOVA with post hoc RIR Tukey’s 
test; ** p <0.01.
However, Cr3+ ions were used herein as activator of coupling of proteins to 
erythrocyte membrane. Since chromium is also a well known contact allergen [19], 
this rises some doubts regarding the actual agent altering mouse erythrocytes to make 
them tolerogenic, whether indeed it is a protein or chromium ions. To address these 
concerns, we had treated mouse syngeneic erythrocytes as for coupling with protein 
antigen, but without adding it. Then, such chromium-treated erythrocytes were 
injected intravenously to mice prior to sensitization with PCL or OX hapten, but in 
both cases it failed to suppress elicited CHS ear swelling (Fig. 3a and 3b, Group C vs 
B and A). Apparently, effi  cient tolerization could be achieved by tolerogen composed 
of the complex allergenic molecule bound to membrane of syngeneic erythrocyte.
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Fig. 3. Chromium ions (Cr3+) failed to make intravenously (iv) administered syngeneic mouse red 
blood cells (MRBC) suppressive in a. oxazolone (OX) and b. trinitrophenol (TNP)-induced contact 
hypersensitivity (CHS) response. Mice were injected intravenously on day 0 and 4 with 0.2 ml of 
10% DPBS suspension of either Cr3+/MRBC, OX-MRBC or TNP-MRBC. Th ree days later mice were 
epicutaneously (ec) sensitized with 0.15 ml of either 3% OX solution or 5% trinitrophenyl chloride 
(picryl chloride, PCL) solution, and on day 12 mice were ear challenged with 0.01 ml of 0.4% OX or PCL 
solution to elicit CHS ear swelling, measured 24 hours later with an engineer’s micrometer. Results, aft er 
subtracting of background increase of ear thickness in non-sensitized but challenged mice, are shown as 
delta; i.e. net value of ear swelling [U × 10–2 mm] ± standard error (SE). One-way ANOVA with post hoc 
RIR Tukey’s test; ** p <0.01.
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Intravenously administered allergen induces immune tolerance only when 
bound to membrane of syngeneic erythrocytes
As mentioned above, the complex allergen molecules bound to cell membrane 
and administered intravenously effi  ciently induced immune tolerance. However, it 
still remained unclear whether coupling of allergen to cell membrane is absolutely 
essential. To resolve this issue, we have chosen the OVA-induced DTH model [15]. 
Firstly, because we have initially found that DTH to OVA could also be suppressed by 
intravenous administration of OVA-coupled MRBC [5–12], and secondly to avoid the 
uncontrolled binding of intravenously delivered, soluble hapten to membrane proteins 
of self erythrocytes in mouse recipient circulation [3, 20]. Th us, we have intravenously 
administered mice with a high dose of OVA solution in DPBS prior to intradermal 
immunization with OVA, but it failed to aff ect subsequently elicited DTH ear swelling 
response, in contrast to OVA-coupled MRBC (Fig. 4, Group B vs C and  A). Th is 
observation has ultimately proved that binding of allergen to cell membrane prior to 
intravenous administration is crucial for induction of immune tolerance.
Fig. 4. Intravenously (iv) administered high dose of ovalbumin (OVA) suppress OVA-induced delayed-
type hypersensitivity (DTH) response only aft er coupling with syngeneic mouse red blood cells 
(MRBC). Mice were injected intravenously on day 0 and 4 either with 1 mg of OVA in 0.2 ml of DPBS 
or with 0.2 ml of 10% DPBS suspension of OVA-MRBC. On days 7 and 8 mice were intradermally (id) 
immunized with total volume of 0.2 ml of 0.5 mg/ml OVA solution in physiological saline, and on day 
12 mice were ear challenged with 0.01 ml of 0.5 mg/ml OVA solution in physiological saline to elicit 
DTH ear swelling, measured 24 hours later with an engineer’s micrometer. Results, aft er subtracting 
of background increase of ear thickness in non-sensitized but challenged mice, are shown as delta; i.e. 
net value of ear swelling [U × 10–2 mm] ± standard error (SE). One-way ANOVA with post hoc RIR 
Tukey’s test; *** p <0.005.
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Discussion
Depending on the route of its administration, antigen could be either immunogenic 
or tolerogenic [20]. Th is observation is important in attempts to induce immune 
tolerance to chosen antigens. Accordingly, while intradermal immunization of 
mice with OVA provokes the development of DTH response [15], oral delivery of 
this protein induces immune tolerance mediated by extracellular vesicles, so-called 
tolerosomes [21, 22]. Furthermore, oral tolerance to OVA could be induced by 
feeding mice with modifi ed probiotic bacteria secreting OVA [23]. Along these lines, 
skin-induced immune suppression could be achieved by epicutaneous application 
of haptenated protein antigens [24]. Furthermore, epicutaneous immunization with 
myelin basic protein prior to induction of experimental autoimmune encephalitis 
occurred to activate regulatory cells preventing the development and ameliorating 
disease severity [24]. Recently this mechanism was translated into therapy of multiple 
sclerosis in human beings [25].
Similarly, contact sensitizing haptens, when administered intravenously, were 
found to impair the reactivity of immune cells [20]. Detailed analysis of this 
phenomenon suggested that haptens bound to self cell membrane act as tolerogens [3]. 
Simultaneously, it was shown that intravenously administered, hapten-coupled 
syngeneic erythrocytes activate in mice Ts cells, down-regulating CHS reaction to 
this hapten [3, 20]. However, the mechanism of tolerance induction by intravenously 
administered, hapten-coupled syngeneic erythrocytes remained weakly understood. 
Th e current studies investigating the immune eff ects induced in mice by intravenously 
administered contact allergens coupled to syngeneic erythrocytes brought two 
interesting new fi ndings. Firstly, it was proved that intravenously delivered, allergen-
coupled syngeneic erythrocytes do not activate the development of DTH eff ector cells, 
and secondly that the resulting immune tolerance is induced by complex allergens 
bound to self cell membrane. On the other hand, it was confi rmed in another hapten 
system that the actual specifi city of induced immune tolerance is determined by the 
sensitizing allergen. Th us, this observation seems to make the studied mechanism of 
tolerance induction more general than previously concerned.
Along these lines, one can speculate that the tolerogenic effect of allergens 
bound to membranes of self cells developed in fact as preventive mechanism against 
immunization to cell membrane proteins altered by such allergens. An indirect 
evidence that may confi rm this speculation is brought by considering the type II 
allergy, drug-induced cytopenia especially, in which not all of drug-treated patients 
become sensitized. Instead, those individuals that developed the clinical manifestations 
of drug-induced allergic reaction are recognized as prone to sensitizing agents. 
However, it could be hypothesized that their susceptibility to allergens may partly 
results from breaking of immune tolerance. Drug-induced cytopenia results from 
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binding of accumulated in plasma drug-derivatives of hapten trait to cell membrane 
structures, followed by generation of hapten-specifi c IgG forming immune complexes 
with haptenated self antigens of blood cells [26]. However, drug-derived haptens likely 
bind to self blood cells of individuals not developing clinical signs of type II allergy 
as well. Th us, this may refl ect the tolerogenic activity of described herein allergen-
coupled self erythrocytes aft er intravenous administration. Similar tolerogenic eff ect 
was also suggested in the case of intravenous administration of a high dose of soluble 
hapten, shown to rapidly conjugate to circulating blood cells [3]. Altogether, these 
fi ndings imply that haptens and allergens, when bound to plasma membrane of self 
cells in the circulation, act as tolerogen, so thus development of allergic reaction is 
caused by breaking of the induced immune tolerance. Since the eff ector phase of 
type II allergy involves cytolysis of haptenated self cells bearing immune complexes 
on their surface [26], such tolerance mechanism may be considered protective 
against destruction of self cells altered by nonpathogenic agents, that is observed in 
autoimmunity.
Immune tolerance induced by intravenously administered syngeneic erythrocytes 
coupled with allergen was found to be mediated by CD8+ Ts cells, that are lacking 
the expression of classical regulatory T cell markers, like FoxP3 [5], which suggests 
that they belong to population of naturally-occurring suppressor T lymphocytes [27]. 
Th ose were proposed to be involved in maintenance of immune tolerance to self 
antigens [28], and to control macrophage immune functions, including phagocytosis 
and presentation of antigens [29]. CD8+ Ts cells induced by contact allergen-coupled 
self erythrocytes suppress DTH response to subsequently immunizing allergen by 
releasing miRNA-150-carrying exosomes coated with hapten-specifi c LCs ensuring 
the specifi city of immune tolerance [5–12, 20]. Notably, our research fi ndings suggest 
that alteration of self cell membrane by allergen binding is enough to induce Ts cell-
mediated immune tolerance to nonpathogenic agents. Th is has a great translational 
potential in such conditions as allergies and hypersensitivity-related autoimmune 
disorders or immune responses to antigens of transplanted organs.
Induction of tolerant Ts cells by intravenous delivery of a high dose of allergen-
coupled erythrocytes to some extent resembles the activation of tolerance after 
exposure to high doses of allergen, observed in the case of beekeepers and owners 
of domestic animals, cats especially [30]. Th us, described herein immune tolerance 
mechanism could presumably be classified as naturally-occurring. On the other 
hand, our current research findings imply that self blood cells could constitute 
an allergen-delivery system for utilizing in allergen-specifi c immunotherapy [30], 
thereby contributing to inducible mechanisms of immune tolerance. Furthermore, 
other studies revealed that the type of cell used for coupling with allergen seems not 
to have a crucial impact on induction of immune tolerance [3]. Consequently, one 
can speculate that the tolerant state could be induced in each condition associated 
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with the formation of allergen-self cell membrane conjugates. It is worth noting that 
currently studied haptens and protein antigens belong to a group of contact allergens. 
Th erefore, described herein mechanism of tolerance induction also applies to DTH-
related disorders, including contact dermatitis.
Another important discovery of the present study proves that intravenously 
administered contact allergens are deprived of their immunizing properties by binding 
to membranes of self cells, since they failed to induce the maturation of CHS eff ector 
cells. Th is observation additionally supports the aforementioned assumption regarding 
the possibility of clinical utilization of allergen-self cell membrane conjugates, acting 
as tolerogen, in allergen-specifi c immunotherapy. Accordingly, from the clinical point 
of view, it would also be interesting to investigate whether Ts cell-mediated tolerance 
could be induced by application of tolerogen via other, less invasive routes, oral 
especially.
To summarize, our current research contributes to the recognition of recently 
discovered tolerance mechanism by bringing new knowledge on the process of 
Ts cell induction by intravenous administration of allergen-coupled syngeneic 
erythrocytes. We found that intravenously delivered, contact allergen-coupled 
syngeneic erythrocytes induce tolerant state, instead of DTH eff ector cells, and that 
the resulting immune tolerance is induced by complex allergen molecules conjugated 
to plasma membrane of self cells. Furthermore, we have verifi ed the observation that 
the specifi city of CHS suppression is determined by the sensitizing hapten. Th erefore, 
our current fi ndings seem to have signifi cant clinical implications.
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BSA — bovine serum albumin
CHS — contact hypersensitivity
DPBS — Dulbecco’s phosphate-buff ered saline
DTH — delayed-type hypersensitivity
LCs — light chains
MHC — major histocompatibility complex
MRBC — mouse red blood cells
OVA — ovalbumin
OX — oxazolone
PCL — picryl (trinitrophenyl) chloride
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